Survive Today: Reminding heart attack victims about the importance of calling 9-1-1 for medical attention, even during COVID-19

Every 40 seconds, someone in the United States has a heart attack. But since the COVID-19 pandemic, too many people having heart attacks have avoided hospitals out of fear of contracting the virus. The fact is, not seeking immediate medical attention for a heart attack is a serious risk that can that lead to life-threatening complications—even death.

Recognizing AstraZeneca’s ongoing commitment to the patients we serve, we stand with you, to help provide access to continued care, support, and education. Through our efforts, we wish to remind our patients that we at AstraZeneca open our hearts to all of you, especially during these challenging times.  That's why we’re working hard to remind heart attack patients to seek the care they need, ensuring that they are treated safely and professionally in the hospital.

If you or someone you love is experiencing a heart attack, don’t wait. At the first sign of any of the following symptoms, call 9-1-1 immediately or get to a hospital right away.

Heart attacks can happen very suddenly, but most heart attacks start slowly with mild pain. The signs can vary between men and women, as women tend to have lesser-known or more subtle symptoms than men. These symptoms may leave women more vulnerable, since their symptoms could be more easily ignored or mistaken for a less threatening condition.

Ignoring any of these symptoms could put you or your loved one in a potentially life-threatening situation. At the first sign of any of these symptoms, don’t hesitate – call 9-1-1 right away. The dispatcher can help determine the severity of your symptoms, and if needed, will get you the medical attention you need right away. Because heart attacks need to be treated now just as they always were – in the hospital.

For patients living with cardiovascular disease, chronic kidney disease, and diabetes, visit Our Hearts Are Open to get more COVID-19–related resources and support programs from AstraZeneca and its advocacy partners.

US-42411 Last Updated 6/20